United Capital Financial Advisors LLC Invests $380.76 Million in Repligen Corporation $RGEN

Key Points

• United Capital Financial Advisors acquired 2.79 million Repligen shares valued at approximately $380.8 million, making the position 2.1% of its portfolio and giving it a 4.94% stake in the company.
• Repligen reported quarterly EPS of $0.54, exceeding the $0.45 analyst consensus, while revenue rose 11.9% year over year to $204.1 million. The company maintained fiscal 2026 EPS guidance of $2.03–$2.09.
• Analyst sentiment remains positive, with a consensus “Buy” rating and a $166.43 price target, although the stock’s valuation is elevated at roughly 249 times earnings.

United Capital Financial Advisors LLC acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The fund acquired 2,790,650 shares of the biotechnology company's stock, valued at approximately $380,756,000. Repligen makes up about 2.1% of United Capital Financial Advisors LLC's holdings, making the stock its 10th largest position. United Capital Financial Advisors LLC owned 4.94% of Repligen at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in RGEN. Price T Rowe Associates Inc. MD lifted its holdings in Repligen by 31.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company's stock valued at $753,603,000 after purchasing an additional 1,091,683 shares in the last quarter. Opti Capital Management LP bought a new position in shares of Repligen in the fourth quarter worth approximately $2,399,209,000. Wasatch Advisors LP boosted its position in shares of Repligen by 27.9% in the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company's stock worth $216,974,000 after purchasing an additional 346,720 shares during the period. Maverick Capital Ltd. purchased a new stake in shares of Repligen in the first quarter worth $178,946,000. Finally, Invesco Ltd. increased its stake in shares of Repligen by 43.9% in the fourth quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company's stock worth $205,880,000 after purchasing an additional 383,399 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Insider Activity at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of the stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer owned 19,359 shares of the company's stock, valued at $2,807,055. This represents a 3.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.60% of the stock is owned by company insiders.

Repligen Price Performance

RGEN stock opened at $182.03 on Friday. Repligen Corporation has a one year low of $100.99 and a one year high of $188.73. The company's fifty day moving average price is $151.11 and its 200-day moving average price is $132.79. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The company has a market capitalization of $10.27 billion, a PE ratio of 249.36, a price-to-earnings-growth ratio of 3.29 and a beta of 1.03.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping analysts' consensus estimates of $0.45 by $0.09. The firm had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. Repligen's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, equities analysts anticipate that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of analyst reports. Royal Bank Of Canada started coverage on shares of Repligen in a research note on Thursday, May 14th. They set an "outperform" rating and a $160.00 target price on the stock. HSBC cut their price target on Repligen from $170.00 to $150.00 and set a "buy" rating for the company in a research note on Wednesday, June 3rd. Wells Fargo & Company raised their price target on Repligen from $180.00 to $185.00 and gave the company an "overweight" rating in a report on Thursday, July 30th. Zacks Research upgraded Repligen from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 30th. Finally, Citigroup raised Repligen to a "buy" rating in a research note on Tuesday, July 7th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $166.43.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source